Literature DB >> 21603999

Angiogenic activity of sera from pulmonary tuberculosis patients in relation to IL-12p40 and TNFα serum levels.

Tadeusz M Zielonka1, Urszula Demkow, Dorota Michalowska-Mitczuk, Malgorzata Filewska, Beata Bialas, Katarzyna Zycinska, Michael H Obrowski, Jan Kus, Ewa Skopinska-Rozewska.   

Abstract

The role of angiogenesis in the pathogenesis of tuberculosis (TB) is not clear. The aim of this study was to examine the effect of sera from TB patients on angiogenesis induced by different subsets of normal human mononuclear cells (MNC) in relation to IL-12p40 and TNFα serum levels. Serum samples from 36 pulmonary TB patients and from 22 healthy volunteers were evaluated. To assess angiogenic reaction the leukocytes-induced angiogenesis test according to Sidky and Auerbach was performed. IL-12p40 and TNFα serum levels were evaluated by ELISA. Sera from TB patients significantly stimulated angiogenic activity of MNC compared to sera from healthy donors and PBS (p < 0.001). The number of microvessels formed after injection of lymphocytes preincubated with sera from TB patients was significantly lower compared to the number of microvessels created after injection of MNC preincubated with the same sera (p < 0.016). However, the number of microvessels created after the injection of lymphocytes preincubated with sera from healthy donors or with PBS alone was significantly higher (p < 0.017). The mean levels of IL-12p40 and TNFα were significantly elevated in sera from TB patients compared to healthy donors. We observed a correlation between angiogenic activity of sera from TB patients and IL-12p40 and TNFα serum levels (p < 0.01). Sera from TB patients constitute a source of mediators that participate in angiogenesis and prime monocytes for production of proangiogenic factors. The main proangiogenic effect of TB patients' sera is mediated by macrophages/monocytes. TNFα and IL-12p40 may indirectly stimulate angiogenesis in TB.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21603999      PMCID: PMC3140944          DOI: 10.1007/s00408-011-9291-6

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  47 in total

Review 1.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

Authors:  A W Griffioen; G Molema
Journal:  Pharmacol Rev       Date:  2000-06       Impact factor: 25.468

2.  The Immunopathogenesis of Granulomatous Inflammation Induced by Mycobacterium tuberculosis

Authors: 
Journal:  Methods       Date:  1996-04       Impact factor: 3.608

3.  Increased expression of IL-12 receptor mRNA in active pulmonary tuberculosis and sarcoidosis.

Authors:  R A Taha; E M Minshall; R Olivenstein; D Ihaku; B Wallaert; A Tsicopoulos; A B Tonnel; R Damia; D Menzies; Q A Hamid
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

4.  Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis.

Authors:  W Matsuyama; T Hashiguchi; K Matsumuro; F Iwami; Y Hirotsu; M Kawabata; K Arimura; M Osame
Journal:  Am J Respir Crit Care Med       Date:  2000-09       Impact factor: 21.405

Review 5.  Eales' disease: oxidant stress and weak antioxidant defence.

Authors:  S Ramakrishnan; M Rajesh; K N Sulochana
Journal:  Indian J Ophthalmol       Date:  2007 Mar-Apr       Impact factor: 1.848

6.  TNFalpha and INFgamma inducing capacity of sera from patients with interstitial lung disease in relation to its angiogenesis activity.

Authors:  T M Zielonka; U Demkow; E Puscinska; A Golian-Geremek; M Filewska; K Zycinska; B Białas-Chromiec; K A Wardyn; E Skopińska-Rózewska
Journal:  J Physiol Pharmacol       Date:  2007-11       Impact factor: 3.011

7.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Authors:  A Kraft; K Weindel; A Ochs; C Marth; J Zmija; P Schumacher; C Unger; D Marmé; G Gastl
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

Review 8.  Sarcoidosis: immunopathogenetic concepts and their clinical application.

Authors:  J Müller-Quernheim
Journal:  Eur Respir J       Date:  1998-09       Impact factor: 16.671

9.  Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions.

Authors:  Enas A Hamed; Amira M El-Noweihi; Ashraf Z Mohamed; Azza Mahmoud
Journal:  Respirology       Date:  2004-03       Impact factor: 6.424

Review 10.  The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease.

Authors:  Michael P Keane; Robert M Strieter
Journal:  Respir Res       Date:  2001-10-15
View more
  4 in total

Review 1.  Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.

Authors:  Dilara Kiran; Brendan K Podell; Mark Chambers; Randall J Basaraba
Journal:  Semin Immunopathol       Date:  2015-10-28       Impact factor: 9.623

2.  Epigenetic reader BRD4 supports mycobacterial pathogenesis by co-modulating host lipophagy and angiogenesis.

Authors:  Tanushree Mukherjee; Bharat Bhatt; Praveen Prakhar; Gaurav Kumar Lohia; R S Rajmani; Kithiganahalli Narayanaswamy Balaji
Journal:  Autophagy       Date:  2021-06-28       Impact factor: 13.391

3.  Suitability of saliva for Tuberculosis diagnosis: comparing with serum.

Authors:  Anna Ritah Namuganga; Novel N Chegou; Paul Mubiri; Gerhard Walzl; Harriet Mayanja-Kizza
Journal:  BMC Infect Dis       Date:  2017-08-31       Impact factor: 3.090

4.  Mycobacteria employ two different mechanisms to cross the blood-brain barrier.

Authors:  Lisanne M van Leeuwen; Maikel Boot; Coen Kuijl; Daisy I Picavet; Gunny van Stempvoort; Susanne M A van der Pol; Helga E de Vries; Nicole N van der Wel; Martijn van der Kuip; A Marceline van Furth; Astrid M van der Sar; Wilbert Bitter
Journal:  Cell Microbiol       Date:  2018-05-30       Impact factor: 3.715

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.